Sirius Genomics Receives NRC-IRAP Funding for Development of New Biomarkers

By Sirius Genomics Inc., PRNE
Monday, October 4, 2010

VANCOUVER, October 5, 2010 - Sirius Genomics, a developer of companion diagnostics, announced today
that it has signed its second Contribution Agreement with the National
Research Council
of Canada Industrial Research Assistance Program (NRC-IRAP).

This research funding will be applied to discovery of genomic biomarkers
that are predictive of patient response to therapeutics used in critical care
medicine leading to improved disease outcomes.

Chris Wagner, President and CEO of Sirius Genomics, comments, "NRC-IRAP's
continued support reflects the Canadian Government's commitment to scientific
innovation and support for the growth of Canadian companies. Funding from
NRC-IRAP will help us advance our pipeline of companion diagnostics."

About Sirius Genomics: www.siriusgenomics.com

Sirius Genomics develops companion diagnostics (CDx) that are closely
tied to therapeutic decisions, leading to better patient outcomes through
personalized medicine. Sirius generates value by improving the safety and
effectiveness of pharmaceutical compounds. The Company correlates patient
genetics with clinical outcomes, leading to proprietary and commercially
viable CDx products that enable better drug treatment. The Company's first
product is a genetic predictor of response to treatment for sepsis, a severe
blood infection.

This release contains forward-looking statements that are not based on
historical fact. These forward-looking statements involve risks,
uncertainties and other factors that may cause the actual results, events or
developments to be materially different from those expressed or implied by
such forward-looking statements. Readers are cautioned not to place undue
reliance on such forward-looking statements.

For further information: Kamran Alam, Senior Director, Business
Development, Sirius Genomics, +1-604-484-7195, kalam@siriusgenomics.com

For further information: Kamran Alam, Senior Director, Business Development, Sirius Genomics, +1-604-484-7195, kalam at siriusgenomics.com

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :